Novo Nordisk Faces Investor Pressure to Pursue M&A and Pipeline Diversification Beyond Ozempic

The Quick Take

• Investors are pressing Novo Nordisk to accelerate dealmaking and develop new drug candidates as Ozempic's competitive moat faces growing pressure
• Novo prepares to face shareholders at its annual general meeting with calls for a clearer M&A and pipeline strategy beyond GLP-1 dominance
• Revenue concentration in the GLP-1 franchise creates strategic risk as Eli Lilly and pipeline entrants intensify competition

Novo Nordisk faces shareholder pressure ahead of its AGM to articulate a pipeline diversification strategy that reduces dependence on its blockbuster GLP-1 franchise anchored by Ozempic and Wegovy. The Financial Times reports that investors are calling for accelerated dealmaking to expand into adjacencies — including cardiovascular, rare disease, and metabolic disorder pipelines — and to develop new drug classes that could sustain revenue growth beyond the 2028-2030 peak-sales window currently priced in.

The pressure reflects a structural concern in the market: Novo's share price has already been discounting significant Ozempic longevity, but rival GLP-1 drugs from Eli Lilly (Mounjaro, Zepbound) and a wave of next-generation oral GLP-1s in late-stage trials are compressing the timeline to competitive erosion. Novo's cash generation — approximately $10B+ annually at current run rates — provides ample M&A firepower, but management has historically preferred organic development, which creates a credibility gap with investors who see an urgency window.

Key metrics to monitor include Novo's AGM vote outcomes on capital allocation resolutions, any post-meeting M&A announcements, and quarterly Ozempic sales growth deceleration as the first signal that GLP-1 market share is being contested in earnest. Investors should also track Novo's Phase 3 pipeline readouts in cardiovascular and rare disease — these will determine whether organic diversification can close the dependency gap.

Synthesized from 1 source.